^
    11d
    Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer. (PubMed, Front Oncol)
    Selpercatinib and pralsetinib are the most frequently studied RET inhibitors. Notably, research on next-generation RET inhibitors as monotherapy approaches (e.g., LOXO-260, enbezotinib, SY-5007 and TY-1091) is currently underway...While selective RET inhibitors have demonstrated therapeutic potential, concerns regarding drug resistance and toxicity persist. Therefore, future strategies should prioritize the development of next-generation inhibitors and the optimization of combination regimens to improve outcomes for RET-altered thyroid cancer patients.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib) • SY-5007 • TY-1091 • enbezotinib (TPX-0046) • LOXO-260
    3ms
    LOXO-NGR-21001: A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Eli Lilly and Company | N=110 --> 70
    Enrollment change
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    5ms
    LOXO-NGR-21001: A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jun 2025 --> Jun 2026
    Trial completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    1year
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Eli Lilly and Company | Trial primary completion date: Jun 2025 --> Sep 2024
    Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    over1year
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Jun 2025 | Trial primary completion date: Apr 2026 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    over3years
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=140, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    almost4years
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (clinicaltrials.gov)
    P1, N=140, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260
    almost4years
    Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (clinicaltrials.gov)
    P=N/A, Available, Eli Lilly and Company
    New trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    LOXO-260